Therapeutic Response

v::RET status confers therapeutic sensitivity to Vandetanib in patients with Medullary Thyroid Cancer.

Statements

Source and description
Caprelsa (vandetanib) [product information]. EMA. The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.
Vandetanib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved vandetanib for reimbursement as a monotherapy treatment option for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) that is Rearranged during Transfection (RET) mutation positive.